— STX-721 is a next-generation, highly selective Exon 20 mutant EGFR inhibitor designed for a best-in-class profile to overcome efficacy and toxicity limitations of currently available agents — — Approximately 3,400 patients per year diagnosed with NSCLC tumors that express EGFR with Exon 20 insertion mutations in the United States — — Preclinical data to … [Read more…]
Phase III COMFORT™ study met its primary endpoint with statistically significant improvement and Piclidenoson had an excellent safety profile Can-Fite has licensing deals for the marketing of Piclidenoson for the treatment of Psoriasis in multiple global regions PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of … [Read more…]
World’s only brain-guided heat shock protein induction could help millions affected with neurologic disorders AVENTURA, Fla.–(BUSINESS WIRE)–btt Corp. (btt), a medical technology company focused on the development of innovative devices and treatments for targeted heat shock protein induction, today announced that Oklahoma Rock Holdings, LLC (Oklahoma Rock) has completed an investment of $29.3 million. btt’s … [Read more…]
CAMBRIDGE, Mass. & NASHVILLE, Tenn.–(BUSINESS WIRE)–Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbinger’s novel platform technology for blood-based early cancer detection. The Cancer ORigin Epigenetics- Harbinger Health (CORE-HH) study plans … [Read more…]
RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for drug discovery and development. MDSS will support early-stage biomedical startups with direct investment, access to powerful Azure Cloud computing and opportunities … [Read more…]
Partnership enhances transparency between providers and suppliers IRVING, Texas–(BUSINESS WIRE)–Vizient, Inc. announced today it has entered into a strategic partnership with Supply Risk Solutions to provide a database platform for the collection of healthcare supply pedigree data. The partnership will provide automated supply chain disruption monitoring and risk prevention for Vizient members and is the … [Read more…]
DENVER–(BUSINESS WIRE)–#drugshortages—RISCS, Inc. announced today it has joined a new coalition of diverse stakeholders to address drug shortages in the United States. The End Drug Shortages Alliance (EDSA) provides a forum for key stakeholders to take strategic aim at one of health care’s more pressing and enduring issues, drug shortages that disrupt patient care. “We … [Read more…]
– Series B extension co-led by AyurMaya, an affiliate of Matrix Capital Management, and Leaps by Bayer, with participation from Amgen Ventures. Adds to Existing Investors, including Pfizer Ventures, EcoR1 Capital and Sanofi Ventures. – – Proceeds to expand and diversify platform and pipeline to include mRNA and gene correction therapeutics for central nervous system, … [Read more…]
WINSTON-SALEM, N.C.–(BUSINESS WIRE)–#drugshortagemanagement–OrbitalRX announced today it has joined a new coalition of diverse stakeholders to address drug shortages in the United States. The End Drug Shortages Alliance provides a forum for key stakeholders to take strategic aim at one of health care’s more pressing and enduring issues, drug shortages that disrupt patient care. “Drug shortages … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Pharmaceutical Contract Development & Manufacturing Market by Service, End User – Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The Pharmaceutical Contract Development and Manufacturing Market is expected to grow at a CAGR of 7.5% from 2022 to 2029 to reach $226.35 billion by 2029. Following extensive secondary and primary … [Read more…]
